Cystic fibrosis classification: Difference between revisions
Line 64: | Line 64: | ||
|Decreased half-life | |Decreased half-life | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 19:46, 9 February 2018
Cystic fibrosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cystic fibrosis classification On the Web |
American Roentgen Ray Society Images of Cystic fibrosis classification |
Risk calculators and risk factors for Cystic fibrosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
Cystic fibrosis may be classified according to CFTR protein function abnormality:[1]
Cystic fibrosis classification according to CFTR protein function abnormality | ||
---|---|---|
Class | Type of abnormality | Features |
Class 1 | Lack of production | Most common mutations (Class 2 is the most common mutation worldwide)
Associated with pancreatic insufficiency |
Class 2 | Failure to reach the site of action due to misfolding | |
Class 3 | Defects in gating | |
Class 4 | Conductance | Rarer mutations
Typically do not have pancreatic insufficiency |
Class 5 | Abnormally low channel numbers | |
Class 6 | Decreased half-life |
References
- ↑ Burney TJ, Davies JC (2012). "Gene therapy for the treatment of cystic fibrosis". Appl Clin Genet. 5: 29–36. doi:10.2147/TACG.S8873. PMC 3681190. PMID 23776378.